Due to the incremented expression of TIM-3+ PD-1+ CD8+ T cells in the blood and tumor tissue of CRC patients [100], TIM-3 can be considered a valuable therapeutic target in CRC [101]. This evidence concerns the gene PDCD1 and neoplasm.